Header Logo

Connection

SANJAY DESHPANDE to Sirolimus

Back to Details
This is a "connection" page, showing publications SANJAY DESHPANDE has written about Sirolimus.
SANJAY DESHPANDE
Connection Strength
0.044
Sirolimus
  1. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia. 2022 10; 36(10):2479-2487.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.